SUMMARY In a double-blind controlled trial amylopectin sulphate (Depepsen) had no significant advantage over placebo in the symptomatic treatment of duodenal ulcer.
Most treatments of duodenal ulcer have attempted to neutralise or diminish acid output or to increase mucosal resistance; little attention has been given to pepsin. Amylopectin sulphate (Depepsen, Searle) has been reported to be effective in both gastric and duodenal ulcer (Cayerand Ruffin, 1967; Zimmon, et al., 1969; Sun and Ryan, 1970) , though a negative study has also appeared (Cocking, 1972) . We report here a double-blind trial of this agent in the asymptomatic treatment of duodenal ulcer.
Methods
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either of these two criteria, nor was there any difference in the severity of pain. No side-effects were noted with either amylopectin or placebo tablets. The active and placebo groups were comparable in age, sex, and length of history.
Discussion
These observations show no advantage for amylopectin sulphate compared with placebo in the treatment of symptoms of duodenal ulceration. In both treatment groups daytime and nocturnal pain and antacid consumption decreased during the six weeks of the trial-the decrease presumably representing the spontaneous symptomatic remission in duodenal ulcer. These results differ from the significant benefit with amylopectin sulphate 250 mg two hourly reported by Sun and Ryan (1970) and Sun (1974) . However, in a trial using amylopectin sulphate and propantheline, Cocking (1972) could show no advantage for amylopectin sulphate 500 mg every three hours over a placebo, and in a recent endoscopically controlled eight week trial Landecker et al. (1976) also found no advantage for amylopectin.
Although amylopectin sulphate has been shown to inhibit gastric pepsin activity in man (Sun, 1967) , it did not, in the dose range used in the present trial, produce significant relief of symptoms in patients with duodenal ulceration.
We wish to thank Searle and Co. Ltd., for supplying the active and placebo tablets. 
